Rheumatology Network's Top 5: August 27, 2022

Published on: 

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 27, 2022.

Patients with PsA More Likely to Experience Side Effects of Methotrexate

"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”

Interstitial Lung Disease Increases Mortality Risk in RA

Investigators believe that “screening for comorbidities of COPD and diabetes mellitus with end-organ damage as part of the routine in treating RA-ILD population" may be beneficial.

Cardiology Co-Management May Reduce Hospitalization Rates, Adverse Events in RA

"Cardiovascular manifestations in rheumatoid arthritis can be complex, raising concerns for adequate patient management and provider-dependent roles.”

Paul M Peloso, MD, MSc: Izokibep Significantly Improves Symptoms of Psoriatic Arthritis

Rheumatology Network interviewed Paul M Peloso, MD, MSc, Chief Medical Officer at Acelyrin, to discuss recent phase 2 data examining the safety and efficacy of izokibep in the treatment of psoriatic arthritis.

Pulmonary Involvement More Likely in Treatment-Naïve Pediatric Patients

Although pulmonary complications in pediatric patients may cause functional impairment and increase mortality, studies detecting lung involvement in children with treatment-naïve, newly diagnosed patients with rheumatic disease are scarce.